Mpox Outbreak: What you need to know

This variant is more contagious than previous variants in the region and may be slightly more aggressive than the variant (Clade IIb) that caused a global outbreak in 2022. Although Clade Ib shows increased transmissibility, the mortality rate remains relatively low, around 0.6% in the eastern part of the Democratic Republic of Congo.

The World Health Organization (WHO) has declared this outbreak a global public health emergency. As of now, no cases of the Clade Ib variant have been reported in Belgium (status: August 20, 2024), and the risk of infection for the general population remains very low. Therefore, there is no immediate cause for concern. Our researchers and medical experts are closely monitoring the situation and adjusting our recommendations as necessary.

While the situation is under control, we continue to receive many questions about the new variant. That’s why we have put together a comprehensive FAQ that covers the most important information about the new mpox variant, preventive measures, and what to do in the event of a possible outbreak. The FAQ is continuously updated with the latest insights and recommendations.

Here are some of the frequently asked questions:

• What are the symptoms of mpox?

• How do you contract mpox?

• What is mpox and where is it found?

• Can I be vaccinated against the new Clade I variant?

• I’m planning to travel to affected countries, should I be concerned?

For detailed answers and to stay informed about the latest developments, we invite you to visit our FAQ page.

Our expertise in mpox research
The Institute of Tropical Medicine (ITM) has extensive experience researching mpox, built over many years. We are actively involved in the epicenter of this outbreak in the DRC, where we have access to the largest cohort of individuals infected with the new variant. We collaborate with local and international partners in the DRC and bring our experience from managing the previous mpox outbreak in Belgium. Our on-the-ground research focuses on evaluating vaccine effectiveness against the new variant, monitoring its effects on vulnerable populations, and assessing outbreak control measures.

We remain committed to providing you with the most up-to-date and reliable information about mpox.